FDA clears four-dose KwikPen versions of Mounjaro and Zepbound

Patients taking tirzepatide have a new delivery option. The FDA approved the Zepbound KwikPen and the Mounjaro KwikPen on Jan. 20, 2026, clearing six strengths of each device ^[1][2].

The approvals cover supplements to the two brands' existing new drug applications: NDA 217806/S-002 for Zepbound and NDA 215866/S-009 for Mounjaro. Both letters were signed by Lisa B. Yanoff, MD, deputy director of the FDA's Office of Cardiology, Hematology, Endocrinology, and Nephrology ^[1][2].

Each KwikPen is described in the labeling as a multi-dose, single-patient-use prefilled pen that contains four fixed doses, with one dose injected under the skin each week ^[1][2][6]. The six strengths range from 10 mg/2.4 mL, which supplies four 2.5 mg doses, to 60 mg/2.4 mL, which supplies four 15 mg doses. Every injection delivers 0.6 mL ^[3][4].

The review was not quick. Lilly filed the Mounjaro supplement on Sept. 28, 2023, and the Zepbound supplement on Nov. 15, 2023, and each drew a Jan. 29, 2025 action letter from the agency, according to the approval documents. Amendments dated Dec. 2, 2025 answered the FDA's remaining questions, and both supplements were cleared on the same day ^[1][2].

Along with the new devices, both labels gain a Warnings and Precautions entry numbered 5.10, listed in each label's Recent Major Changes table as effective 01/2026. It states that a KwikPen should never be shared between patients, even if the pen needle is replaced ^[3][4]. The patient Instructions for Use gives the reason: sharing can pass a serious infection from one person to another ^[6].

The Instructions for Use walks through the steps — turning the dose knob until it stops and the correct icon appears, priming the pen before every weekly injection, and attaching a new pen needle each time ^[6]. After four doses, the device is built to block a fifth full dose; patients are told to throw the pen away with any medicine still inside rather than inject the leftover or move it into a syringe ^[6]. People who are blind or have vision problems should not use the pen without help from someone trained to use it ^[6].

Lilly said on Feb. 23, 2026 that the Zepbound KwikPen is available, with a self-pay price starting at $299 per month for the 2.5 mg strength ^[5]. That strength is the recommended starting dose on the Zepbound label ^[3]. Pricing for the other five strengths, and any launch timing for the Mounjaro KwikPen, have not been disclosed ^[5].

"As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the U.S. for other Lilly medicines," Ilya Yuffa, executive vice president and president of Lilly USA, said in the company's announcement ^[5].

The approved uses did not change. Zepbound is indicated, alongside a reduced-calorie diet and increased physical activity, for adults with obesity or with overweight plus at least one weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity ^[3]. Mounjaro is indicated for type 2 diabetes in adults and in children 10 and older, and to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk ^[4].

Why it matters for patients

A single-dose pen and a vial option remain on both labels, so the KwikPen adds a choice rather than replacing what exists ^[3][4]. One pen covering four weekly injections means fewer devices to store and dispose of each month. Clinical pharmacist Susan Cornell, writing in a published commentary, noted that some patients see single-use pens as excessive waste, that a mistake in injection technique can waste a single-use dose, and that drawing from a vial suits some people better than others ^[5].

The sharing warning is the other practical change. Reusing a pen across people risks a serious infection even when the needle is new ^[3][4][6]. How often that has happened has not been reported, and the approval letters include no case counts ^[1][2].

Cost remains the open question. The announced $299 monthly self-pay figure applies only to the 2.5 mg strength ^[5]. Whether insurers will cover the KwikPen, and whether that coverage would differ from the single-dose pens and vials already on the market, has not been reported.

What happens next

Under the letters, Lilly must file updated structured product labeling within 14 days, submit final printed carton and container labeling within 30 days of printing, and provide patent information for Orange Book listing within 30 days of approval ^[1][2]. The FDA also asked the company to change carton wording from "mg/dose" to "mg per dose" ^[1][2].